How Daiichi Sankyo Aims to Become a Top Five Oncology Player by 2035

Why It Matters

The strategy ties Daiichi’s future growth to high‑margin ADCs, positioning it to capture a larger share of the fast‑growing oncology market and to offset competitive pressures through innovation and cost savings.

Key Takeaways

• Enhertu and Datroway drive majority of Daiichi's projected $19bn sales
• DXd platform targets B7‑H3, CDH6, HER3 in late‑stage trials
• FDA lifted hold on ifinatamab deruxtecan after safety protocol changes
• Company plans $18.5bn R&D spend and AI cost cuts of $1.3bn
• Goal: top‑five global oncology firm by 2035

Pulse Analysis

The ADC arena has become a cornerstone of modern oncology, marrying antibody specificity with potent cytotoxic payloads. Daiichi Sankyo’s DXd technology distinguishes itself by optimizing linker stability and payload delivery, a formula that propelled Enhertu to blockbuster status across breast, gastric and lung cancers. This technical edge not only validates the company’s platform but also sets a high bar for rivals scrambling to develop next‑generation conjugates, making ADCs a decisive battleground for market share and therapeutic breakthroughs.

Beyond its flagship products, Daiichi is diversifying its pipeline with three late‑stage candidates—ifinatamab deruxtecan, raludotatug deruxtecan and patritumab deruxtecan—each targeting distinct tumor antigens. Partnerships, notably the $5.5 billion collaboration with Merck, amplify development resources while sharing risk. Regulatory hurdles, such as the temporary FDA hold on the SCLC trial, underscore the safety complexities inherent to ADCs, yet the swift reinstatement demonstrates the company’s agility in addressing safety signals. These assets, together with emerging DXd‑based programs like DS‑3939 and DS‑3790, aim to broaden revenue beyond the HER2 and TROP2 niches.

Strategically, Daiichi is betting on sustained innovation and operational efficiency. A projected ¥2.9 trillion ($18.5 billion) R&D outlay over five years will fund not only next‑generation ADC payloads but also exploratory modalities such as STING‑activating conjugates, multispecific antibodies, protein degraders and siRNA therapies. Parallel AI‑driven cost‑optimization initiatives target ¥200 billion ($1.3 billion) in savings, freeing capital for high‑value projects. While competition intensifies, the combination of a proven platform, robust pipeline, and disciplined cost management positions Daiichi Sankyo to potentially achieve its 2035 ambition of becoming a top‑five oncology leader.